Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance
Key Highlights
- ➤2026 revenue guidance cut to $13.5 million-$14.5 million from $16 million-$18 million
- ➤Q3 revenue $4.0 million, down 3% year over year
- ➤Q3 net loss narrowed to $13.7 million from $18.2 million
- ➤Cash, equivalents and investments totaled approximately $198.1 million
- ➤ITC staff recommended full exclusion and cease-and-desist orders against Nanomics Biotechnology
Expert Statements
Omid Farokhzad, Chair and Chief Executive Officer of Seer
“This quarter, our customers continued to demonstrate what Proteograph makes possible, from new discoveries in population-scale research to emerging applications in AI, while established customers returned to purchase consumables and new pharmaceutical customers adopted the platform.”
Omid Farokhzad, Chair and Chief Executive Officer of Seer
“Proteograph fundamentally expands the biology researchers can see with mass spectrometry.”
Omid Farokhzad, Chair and Chief Executive Officer of Seer
“Our focus is to translate that differentiated value into sustained revenue growth by expanding sample volume within customer accounts and building relationships that support repeat use.”
Omid Farokhzad, Chair and Chief Executive Officer of Seer
“With a strong balance sheet and growing evidence of the platform’s value, I remain confident in Seer’s opportunity and committed to building long-term value for our shareholders.”
REDWOOD CITY, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended September 30, 2026.
Seer reported third-quarter revenue of $4.0 million, compared with $3.1 million in the second quarter of 2026, and ended the quarter with approximately $198.1 million in cash, cash equivalents and investments. Seer also updated its full-year 2026 revenue guidance to a range of $13.5 million to $14.5 million.
Get started
Create a free account to read the full story.